Analysts think VERV stock price could increase by 209%
Feb 24, 2025, 12:25 PM
-19.60%
What does VERV do
Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
10 analysts think VERV stock price will increase by 208.67%. The current median analyst target is $22.44 compared to a current stock price of $7.27. The lowest analysts target is $14.14 and the highest analyst target is $33.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
